CGEM - NASDAQ
Cullinan Therapeutics, Inc.
$15.21
-0.85%Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.
At a Glance
Live SnapshotCullinan Therapeutics, Inc. Profit Bridge
Profitability Analysis
Cullinan Therapeutics, Inc. Income Statement
CGEM • NASDAQ
| Cullinan Therapeutics, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||
0.0 | 0.0 | 0.0 | 0.0 | 18.9M | 0.0 | 0.0 | 0.0 | |
GROSS PROFIT | ||||||||
(311K) | (306K) | (0.0) | (0.0) | (0.0) | (62K) | (70K) | (43K) | |
-311K | -306K | 0.0 | 0.0 | 18.9M | -62K | -70K | -43K | |
OPERATING INCOME | ||||||||
(241.6M) | (196.6M) | (191.1M) | -144.6M | (86.9M) | (60.3M) | (22.3M) | (14.6M) | |
(54.2M) | (53.7M) | (42.5M) | (40.2M) | (29.1M) | (17.1M) | (5.5M) | (5M) | |
(187.4M) | (142.9M) | (148.2M) | (91.9M) | (57.8M) | (43.2M) | (16.8M) | (9.6M) | |
-241.6M | -196.9M | -191.1M | 144.6M | -68M | -60.3M | -22.3M | -14.6M | |
PRE-TAX INCOME | ||||||||
22.2M | 29.7M | 21.6M | 6.6M | 477K | 888K | 620K | 0.0 | |
(0.0) | (0.0) | (440K) | -276.8M | (0.0) | (0.0) | (0.0) | (0.0) | |
21.8M | 29.5M | 21.9M | 6.7M | 469K | 877K | 616K | 397K | |
-219.9M | -167.5M | -169.2M | 151.3M | -67.5M | -59.5M | -21.7M | -14.2M | |
NET INCOME | ||||||||
(0.0) | (117K) | -14.1M | (42.1M) | (0.0) | (0.0) | (0.0) | (0.0) | |
-219.9M | -167.4M | -153.2M | 111.2M | -65.6M | -51.8M | -20M | -14.2M |
SEC Filings
CGEM - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 18, 2026 | May 18, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | April 27, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 10, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 10, 2026 | March 10, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 08, 2026 | January 08, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 08, 2025 | December 08, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 21, 2025 | November 18, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 |
Related Guides
Continue your CGEM research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.